Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model

Fig. 5

Halofuginone displays an anti-leukemic effect in the in vivo model of APL. a WBC account in peripheral blood obtained non-leukemic (control), leukemic and leukemic mice treated for 21 days with HF (Leuk-HF). b BM-cell spin and spleen imprints from control and leukemic mice. Leishman-Wright-Giemsa staining. c Immnunophenotyping of BM cells from leukemic and leuk-HF. d CD117+CD16/32+ characterize murine promyelocytes and e CD11b+Gr-1+ are double expressed in more differentiated cells

Back to article page